Medtronic projects 6.75%-7.25% organic revenue growth for FY 2027
Medtronic forecasts FY 2027 organic revenue growth of 6.75%-7.25% and EPS of $5.90-$6.00, despite a $250 million tariff impact. The outlook follows Q4 fiscal 2026 earnings.
Medical device news covering implants, diagnostics, recalls, FDA clearances, and medtech company performance.
Medtronic forecasts FY 2027 organic revenue growth of 6.75%-7.25% and EPS of $5.90-$6.00, despite a $250 million tariff impact. The outlook follows Q4 fiscal 2026 earnings.
China's NMPA approved the world's first invasive BCI product, NEO, for use beyond clinical trials. The coin-size implant, developed by Neuracle Technology and Tsinghua University, helps paralyzed patients control a robotic glove. Patient Dong Hui regained writing ability after 11 months of rehabilitation.